Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer

Steven Darryll Heys, T. K. Sarkar, A. W. Hutcheon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Developments in the role of adjuvant and neoadjuvant chemotherapy for the treatment of patients with breast cancer have focused on the taxes, in particular, docetaxel. This paper discusses the rationale for the introduction of docetaxel into the management of patients following surgery and also its role in those patients with locally-advanced disease, focussing on key clinical trials. The addition of docetaxel to standard adjuvant chemotherapeutic regimens does seem to result in an increased survival in some patients with early stage disease. In the neoadjuvant setting, the addition of docetaxel to standard regimens does increase pathological response rates, which is a surrogate marker of eventual outcome.

Original languageEnglish
Pages (from-to)2147-2157
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume5
Issue number10
DOIs
Publication statusPublished - 2004

Keywords

  • adjuvant chemotherapy
  • docetaxel
  • neoadjuvant chemotherapy
  • PROSPECTIVE RANDOMIZED-TRIAL
  • LOCALLY ADVANCED-CARCINOMA
  • COLONY-STIMULATING FACTOR
  • PHASE-II TRIAL
  • PRIMARY CHEMOTHERAPY
  • PREOPERATIVE CHEMOTHERAPY
  • MONOCLONAL-ANTIBODY
  • TUMOR RESPONSE
  • SINGLE-CENTER
  • 3 CM

Cite this

Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer. / Heys, Steven Darryll; Sarkar, T. K.; Hutcheon, A. W.

In: Expert Opinion on Pharmacotherapy, Vol. 5, No. 10, 2004, p. 2147-2157.

Research output: Contribution to journalArticle

Heys, Steven Darryll ; Sarkar, T. K. ; Hutcheon, A. W. / Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer. In: Expert Opinion on Pharmacotherapy. 2004 ; Vol. 5, No. 10. pp. 2147-2157.
@article{1a1198c079954f34a28daad3d9ce33f8,
title = "Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer",
abstract = "Developments in the role of adjuvant and neoadjuvant chemotherapy for the treatment of patients with breast cancer have focused on the taxes, in particular, docetaxel. This paper discusses the rationale for the introduction of docetaxel into the management of patients following surgery and also its role in those patients with locally-advanced disease, focussing on key clinical trials. The addition of docetaxel to standard adjuvant chemotherapeutic regimens does seem to result in an increased survival in some patients with early stage disease. In the neoadjuvant setting, the addition of docetaxel to standard regimens does increase pathological response rates, which is a surrogate marker of eventual outcome.",
keywords = "adjuvant chemotherapy, docetaxel, neoadjuvant chemotherapy, PROSPECTIVE RANDOMIZED-TRIAL, LOCALLY ADVANCED-CARCINOMA, COLONY-STIMULATING FACTOR, PHASE-II TRIAL, PRIMARY CHEMOTHERAPY, PREOPERATIVE CHEMOTHERAPY, MONOCLONAL-ANTIBODY, TUMOR RESPONSE, SINGLE-CENTER, 3 CM",
author = "Heys, {Steven Darryll} and Sarkar, {T. K.} and Hutcheon, {A. W.}",
year = "2004",
doi = "10.1517/14656566.5.10.2147",
language = "English",
volume = "5",
pages = "2147--2157",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer

AU - Heys, Steven Darryll

AU - Sarkar, T. K.

AU - Hutcheon, A. W.

PY - 2004

Y1 - 2004

N2 - Developments in the role of adjuvant and neoadjuvant chemotherapy for the treatment of patients with breast cancer have focused on the taxes, in particular, docetaxel. This paper discusses the rationale for the introduction of docetaxel into the management of patients following surgery and also its role in those patients with locally-advanced disease, focussing on key clinical trials. The addition of docetaxel to standard adjuvant chemotherapeutic regimens does seem to result in an increased survival in some patients with early stage disease. In the neoadjuvant setting, the addition of docetaxel to standard regimens does increase pathological response rates, which is a surrogate marker of eventual outcome.

AB - Developments in the role of adjuvant and neoadjuvant chemotherapy for the treatment of patients with breast cancer have focused on the taxes, in particular, docetaxel. This paper discusses the rationale for the introduction of docetaxel into the management of patients following surgery and also its role in those patients with locally-advanced disease, focussing on key clinical trials. The addition of docetaxel to standard adjuvant chemotherapeutic regimens does seem to result in an increased survival in some patients with early stage disease. In the neoadjuvant setting, the addition of docetaxel to standard regimens does increase pathological response rates, which is a surrogate marker of eventual outcome.

KW - adjuvant chemotherapy

KW - docetaxel

KW - neoadjuvant chemotherapy

KW - PROSPECTIVE RANDOMIZED-TRIAL

KW - LOCALLY ADVANCED-CARCINOMA

KW - COLONY-STIMULATING FACTOR

KW - PHASE-II TRIAL

KW - PRIMARY CHEMOTHERAPY

KW - PREOPERATIVE CHEMOTHERAPY

KW - MONOCLONAL-ANTIBODY

KW - TUMOR RESPONSE

KW - SINGLE-CENTER

KW - 3 CM

U2 - 10.1517/14656566.5.10.2147

DO - 10.1517/14656566.5.10.2147

M3 - Article

VL - 5

SP - 2147

EP - 2157

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -